Long-term evaluation of dexamethasone intravitreal implant in vitrectomized and non-vitrectomized eyes with macular edema secondary to non-infectious uveitis
| Autor: | Laura Pelegrín, M S de la Maza, José Ríos, Blanca Molins, Alfredo Adán |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Adult
Male medicine.medical_specialty Adolescent genetic structures medicine.medical_treatment Visual Acuity Glaucoma Vitrectomy Dexamethasone Macular Edema Retina Ophthalmic pathology Uveitis Neuro-ophthalmology Infectious uveitis Ophthalmology medicine Dexamethasone Intravitreal Implant Humans Child Glucocorticoids Macular edema Intraocular Pressure Aged Aged 80 and over Drug Implants business.industry Middle Aged medicine.disease eye diseases Surgery Intravitreal Injections Retreatment Clinical Study Drug Evaluation Female sense organs business Follow-Up Studies |
| Zdroj: | Eye. 29:943-950 |
| ISSN: | 1476-5454 0950-222X |
| Popis: | To compare dexamethasone (DEX) intravitreal implant effect in non-vitrectomized (non-PPV) vs vitrectomized (PPV) eyes with macular edema (ME) secondary to non-infectious uveitis.Medical records of patients with uveitic ME treated with DEX-intravitreal implant were reviewed. Main outcome measures were changes in central retinal thickness (CRT), best corrected visual acuity (BCVA), intraocular pressure (IOP), vitreous haze and adverse events. Statistical analysis was performed by Longitudinal Linear model using the General Estimating Equation methodology.Forty-two eyes of 32 patients were included. Median follow-up time was 18 months (interquartile range (IQR): 12-24). Median CRT showed its maximum decrease at the first month in non-PPV and PPV eyes without statistically significant differences between both groups (P=NS). Median Snellen BCVA, converted to logarithm (LogMAR), showed its maximum improvement at third month in both groups without statistically significant differences between them (P=NS). Median IOP was higher in non-PPV eyes than in PPV eyes from third (P=0.025) to 12th month (P=0.013). Vitreous haze score improved in both groups since first month and showed no differences (P=0.706). Reinjection was performed in 45.2% of eyes at a median time of 5 months IQR: (5-6). Ocular hypertension (47.6%) was the most common adverse event.DEX-intravitreal implant for uveitic ME has similar long-term safety profile and good response measured in terms of CRT decrease, BCVA, and vitreous haze improvement in both groups. Non-PPV eyes following DEX-intravitreal implant showed higher IOP increase than PPV eyes, showing the need for close IOP monitoring. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|